Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00117
2006-10-14
Prospective
N.A.
Department of Obstetrics & Gynaecology
N.A.
N.A.
Dr. CHAN, Symphorosa Shing Chee
Email symphorosa@cuhk.edu.hk
Dr. SC Chan
Email symphorosa@cuhk.edu.hk
A Randomized, Double-blind, Placebo-controlled Study on Treatment of Nocturia with Desmopressin in Women
N.A.
Yes
2006-04-24
Nocturia
Drug
MINIRIN 0.2 mg tablets containing desmopressin acetate 0.2 mg and excipients q.s. (oral; 1 dose per night for 3 weeks)
Patients will experience 1-week screening period and 3-week double-blind period.
Placebo (oral; 1 dose per night for 3 weeks)
Inclusion criteria: All female patients attending the Urodynamic Clinic at Prince of Wales Hospital and Queen Elizabeth Hospital with nocturia problems.
Exclusion criteria: (1) know alcoholics or drug abusers; (2) pregnant or breast-feeding women; (3) suspicion or evidence of clinically relevant cardiac failure; (4) any history of clinically significant hepatic or renal diseases; (5) any history of uncontrolled hypertension; (6) abnormal level of serum potassium and/or serum creatinine; (7) serum sodium level below normal range; (8) treatment within 30 days of study start with drug or medication known or suspected to interact with desmopressin; (9) hypersensitivity to desmopressin; (10) multiple sclerosis; (11) consistent residual volume >150 ml, as assessed by palpation; (12) shift-workers; (13) diagnosed or suspected diabetes insipidus or primary polydipsia (urine output >40 ml/kg body weight per 24 hours); (14) clinically significant haematuria, bacteriuria, polyuria, proteinuria, glucosuria or ketouria; (15) previous inclusion in this study or other studies of desmopressin; (16) other investigational drugs or medication taken in the past 30 days; (17) patients scheduled for in-patient surgery during this trial; (18) any history of clinically relevant psychiatric disorders within the last 24 months proceeding enrolment in this trial; (19) any history of non-compliance to medical regimens or not compliant with protocol requirements; (20) unable to keep a diary or perform volume measurements on their own
Randomized
Placebo
Double-blind
Parallel
2006-11-28
50/50
Recruiting
Clinical efficacy of oral desmopressin in the treatment of nocturia in women and the effect of desmopressin on the study population with regards to quality of life and safety will be examinated and documented.
N.A.
2011-03-02
Yes
N.A.
|
|
|
|
|
---|---|---|---|---|
No documents yet. |